Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EWTX vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EWTX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 7–1 Matrix Metrics)

EWTX Overall Winner 6-Pillar Tally: EWTX 2 – 2 MESO (2 Tie) Matrix Metrics: EWTX 7 – 1 MESO

As of Nov 16, 2026, Edgewise Therapeutics, Inc. (EWTX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). EWTX carries a Unified Composite Score of 35.4/100 (SELL) at $43.61 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: EWTX earns the overall head-to-head edge with a stronger Unified Composite Score (35.4/100 SELL vs. MESO 35.5/100 SELL) and 1.19β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although EWTX compares more favorably head-to-head, both EWTX (35.4/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: EWTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EWTX vs MESO
EWTX NASDAQ Head-to-Head Winner
Edgewise Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$43.61
-5.05% 1D
Market Cap $5.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 74% Vol
Unified Composite Score
35.4 / 100 SELL
Tech 15.0 Fund 37.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $41.56 · SMA50: $41.34
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (EWTX 2 – 2 MESO)

Columns: Metric · EWTX · MESO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 5.5x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +0.0% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $120M
Market Cap $5.0B $1.7B
3. Profitability & Quality EWTX
Gross Margin N/A 80.0%
Operating Margin 0.0% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) 92.1% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$202M -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $65M Net Cash $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EWTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 133.7% (17th %ile) 76.8% (37th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EWTX (7) vs MESO (1)
Institutional Metric EWTX MESO Criterion Row Edge
Market Capitalization
Scale
$5.0B $1.7B Larger Scale EWTX
Trailing P/E Ratio
Valuation
5.5x N/M Lower Multiple EWTX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
0.0% -42.6% Higher Margin EWTX
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin EWTX
Return on Equity (ROE)
Capital Efficiency
92.1% -9.9% Higher ROE EWTX
52-Week Range Position
Momentum
82% ($20–$49) 6% ($12–$22) Stronger Trend EWTX
Beta / 30D Volatility
Risk Regime
1.19β · 74% Vol 1.18β · 78% Vol Lower Realized Risk EWTX
Unified Institutional Score
Composite Signal
35.4 / 100 (SELL) 35.5 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$202M ($65M Net Cash) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EWTX +23.36 pp
EWTX: +17.26% · MESO: -6.1%
3M Horizon EWTX +24.06 pp
EWTX: -1.13% · MESO: -25.19%
6M Horizon EWTX +52.3 pp
EWTX: +37.48% · MESO: -14.82%
1Y Horizon EWTX +129.99 pp
EWTX: +113.57% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EWTX vs MESO. Trailing 12-month operating profitability (EWTX 0.0% vs MESO -42.6%) and valuation multiples (EWTX N/M vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EWTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E92.1% · N/M
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EWTX CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 133.7%
IV Percentile 17th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EWTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EWTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EWTX vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Edgewise Therapeutics, Inc. (EWTX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). EWTX carries a Unified Composite Score of 35.4/100 (SELL) at $43.61 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: EWTX earns the overall head-to-head edge with a stronger Unified Composite Score (35.4/100 SELL vs. MESO 35.5/100 SELL) and 1.19β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although EWTX compares more favorably head-to-head, both EWTX (35.4/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EWTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: EWTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, EWTX generates N/A in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, EWTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

EWTX and MESO trade at balanced relative valuation multiples. EWTX trades at N/M Forward P/E, 5.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EWTX (92.1% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, EWTX carries 133.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.19β · 74% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.